Enterprise AI
Moving AI Beyond the Pilot (Part 1 - Macro-Level) : Getting the Technology and the People Ready
October 23, 2026 · 7 min read
Insights
Essays by Peter Buniak. Search and filtering run in the browser. The original essays remain on peterbuniak.com, which is the canonical source.
Enterprise AI
October 23, 2026 · 7 min read
Leadership
September 16, 2026 · 5 min read
Life Sciences
July 4, 2026 · 2 min read
14 articles
No articles match that search.
How does a small or mid-sized biotech or pharma company make sure AI delivers on its promises and moves beyond the pilot phase? Technology & Culture.
There is a micro-side that an individual employee or manager can do to ensure the successful AI deployment will deliver on its promises.
The modern CIO’s challenge isn’t simply leading transformation—it’s adapting to constant, increasingly rapid change while balancing innovation, speed, risk, and control. The CIOs best prepared for that environment bring a combination of large-company business experience, consulting adaptability, technology depth, strong leadership, and an entrepreneurial mindset.
Companies say they want CIOs who can move fast and drive change, but when it comes time to hire, they still seem to favor the most predictable résumé. If AI is forcing businesses to rethink how they operate, then consulting, technical, and entrepreneurial experience should count for more than another CIO title on the list.
I believe AI has the potential to fundamentally change how youth sports programs develop athletes—not just by creating better players, but by helping build disciplined, resilient, self-motivated leaders.
The teams that thrive aren't always the most talented. They're the teams where players feel responsible for each other's success, where positivity outweighs negativity, and where leaders set the tone.
An outcomes-focused mindset doesn’t eliminate experimentation—it gives it direction. It helps teams decide which data matters, whether it’s high quality, and whether they’re solving the right problem instead of just building something impressive.
Managing the transition from a clinical-stage company to a commercial company is one of the most exciting and challenging times a Pharma or Biotech company has the privilege of experiencing. But it doesn't come without great planning and a little bit of luck.
The companies that will win over the next decade won’t be the ones that simply adopt AI. They’ll be the ones with leaders who have the courage to think differently, speak up, and turn technology into a competitive advantage.
Historically, FDA interactions were led by Regulatory Affairs, Clinical, Quality, and the business. IT was often brought in later to implement the solution or take part in an audit.That model is quickly becoming outdated.
The starting point for AI in Life Sciences is rarely the technology itself - the foundations of good data, good governance and good people engagement must come first.
AI has drastically changed software engineering over the last year — I jumped back in after a decade to experience it firsthand, building a family app with ChatGPT and Cursor.
The classic sourcing framework — insource core competencies, outsource everything else — is being fundamentally disrupted by AI agents. The new question is: make, buy, or automate?
A path to make IT an innovative function in pharmaceutical and biotech companies — from pharma differentiators to IT guiding principles.